Immunis.AI

Immunis.AI, Inc. is a privately held immuno-genomics company with a patented liquid biopsy platform that provides unique insights into disease biology and personalized assessments. The Intelligentia platform combines the power of the immune system, RNAseq technology, and machine learning (ML) to develop specific disease signatures. This proprietary approach leverages the surveillance mechanisms of the immune system to overcome the limitations of circulating tumor cells (CTC) and cell-free DNA (cfDNA). The platform enhances early disease detection, offering the best chance for a cure when pathogenic factors escape immune surveillance.